Biotech gapper of the morning. Xencor presented Phase 1 data for XmAb819 (an ENPP3 x CD3 bispecific) in advanced clear cell renal cell carcinoma at ESMO on Sunday, and the stock was indicated about +25–27% premarket.
Key numbers
- 119 patients dosed overall; 68 in the three expansion doses
- Confirmed response rates: 30% at 100 mcg/kg (n=30), 44% at 200 (n=25), 45.5% at 400 (n=11)
- Heavily pretreated group: median three prior lines, all had a PD-(L)1 and a VEGFR TKI
- 400 mcg/kg picked as the proposed Phase 3 dose; company wants to discuss an accelerated approval path with the FDA
- Investor webcast was set for this morning
Scalper notes: the headline 45% comes from just 11 patients at the chosen dose, with wide confidence intervals, so expect the bull and bear notes to argue all day. Mid-cap biotech gaps on conference data often see a messy first 15 minutes; I'd wait for the opening range and see whether it holds the premarket high or fills toward the prior close. Premarket volume and spreads matter a lot here, so size small.
Sources: [Xencor press release on Business Wire](https://www.businesswire.com/news/home/ ... PP3-Tumors) | [Benzinga premarket movers](https://www.benzinga.com/trading-ideas/ ... -premarket)
Do you trade ESMO gappers on the open, or wait for the first pullback? Is n=11 enough for you to hold anything overnight?
XNCR ~+25% premarket on ESMO: XmAb819 hits 45% response rate in heavily pretreated kidney cancer — small n, big gap
-
LondonNewsTrader
- Posts: 549
- Joined: Sat Sep 05, 2026 10:13 pm